Bispecific antibodies have become one of the most active modalities in biologics, and their patent landscape is distinctive because a bispecific is an engineered molecule whose format is patented separately from what it binds. A conventional antibody has two identical arms; a bispecific joins two different binding specificities in one molecule, which requires solving a chain-pairing problem so the right heavy and light chains assemble together rather than into mismatched byproducts. Developers solve this in different ways, and each is a distinct region of patenting: fragment-based formats such as the tandem single-chain constructs used in some T-cell engagers; asymmetric full-length formats built on heterodimerization technologies such as knobs-into-holes, common light chains, electrostatic steering, and controlled Fab-arm exchange; and symmetric and dual-variable-domain formats. Reviews of the field have catalogued roughly 100 distinct bispecific formats, reflecting how many ways the two-target strategy can be engineered even before the antigen pair is chosen⁶. Cutting across these is the choice of what the arms bind, one arm against a tumor or disease antigen and, in T-cell engagers, the other against the CD3 receptor to redirect T cells, and the half-life-extension and manufacturing technologies that make the molecule a viable drug. Because the format scaffold, the antigen arms, the effector arm, and the manufacturing method can each be claimed independently and are often held by different owners, freedom-to-operate for a bispecific is a multi-layer, multi-owner analysis rather than a single clearance⁵.

The field has moved decisively into the market, which has raised the stakes across every layer. Fourteen bispecific antibodies had received FDA approval through the end of 2024, nine of them T-cell engagers, roughly double the count from just two years earlier¹. 2025 added further approvals — including the BCMA×CD3 T-cell engager linvoseltamab — carrying the cumulative total past fifteen, alongside a late-stage bispecific pipeline that has grown from about 26 candidates in 2010 to more than 200 today². The approved base spans more than T-cell engagers: the HER2-biparatopic bispecific zanidatamab, for example, received accelerated FDA approval for HER2-positive biliary tract cancer in November 2024, illustrating the non-CD3 side of the field³. Across oncology, hematology, ophthalmology, and hemophilia, the modality has shifted from a research concept into one of the most active areas of biologics development. The competitive structure is bimodal: a small number of established developers hold deep, platform-level format IP built over the last decade and a half, while a rapidly expanding cohort of newer entrants, many based in China, files internationally at scale. Because much of the foundational value sits in the heterodimerization scaffolds rather than in any single antigen, a company can hold a strong position on its target biology and still face freedom-to-operate exposure on the format it uses to build the molecule. Because applications publish about eighteen months after filing, the newest format, target-pair, and conditional-activation filings are under-represented, so the current frontier is more active than granted-patent counts suggest.

The strategic picture turns on where defensible, hard-to-design-around IP sits. The core heterodimerization scaffolds are comparatively crowded and heavily licensed, so the open, high-value ground is increasingly in novel formats that design around them, in new and validated target pairs, in conditional or masked bispecifics that activate only in the tumor environment, in tri- and multispecific molecules, and in adjacent formats such as natural-killer-cell engagers. Expansion beyond oncology, into immunology, ophthalmology, and other areas, opens further target and format space. Reading the landscape by format, arm, and owner, and tracking both the patents and the underlying antibody-engineering research, is what separates a workable position from a blocked one.

What creates FTO risk in bispecific antibodies

Format and heterodimerization-scaffold claims. These cover the technologies that solve chain pairing, such as knobs-into-holes, common light chains, and controlled Fab-arm exchange, a foundational and heavily licensed layer. Knobs-into-holes constructs in particular require dedicated assembly and purification process development to yield correctly paired product at commercial scale, which is why manufacturing IP often tracks format choice closely⁸.

Antigen-binding-arm claims. These cover the variable domains against each target, which can carry their own IP from monoclonal-antibody programs.

Effector-arm claims. These cover the CD3 or other effector-recruiting arm in T-cell engagers, a distinct and contested layer. CD3 engagers act as molecular adaptors that redirect T-cell cytotoxicity toward a tumor antigen by forming an immune synapse, independent of the T cell's native antigen specificity, and this mechanism spans both IgG-based and non-IgG-based architectures⁷. T-cell engagers targeting CD3 alongside a tumor antigen now anchor much of the oncology bispecific pipeline⁴.

Half-life and Fc-engineering claims. These cover Fc modifications for half-life extension and reduced effector function, a separately owned layer.

Manufacturing and purification claims. These cover the expression and purification methods that yield correctly paired molecules at scale, where practical barriers concentrate⁸.

The competitive landscape by the numbers

Cypris's corpus puts the bispecific-antibody and T-cell-engager patent family set at roughly 55,049 families (Cypris corpus, indicative; 2025–26 partial). Filing activity has accelerated sharply, from 468 new families in 2010 to 2,850 in 2019 and 6,295 in 2024, with 2025 (7,589) and 2026 (4,926, partial) continuing to climb (Cypris corpus, indicative; 2025–26 partial). Ownership is concentrated at the top: Regeneron (1,628 families), F. Hoffmann-La Roche (1,362), Genentech (1,174), Genmab (739), Amgen (644), and Chugai (624) lead the assignee ranking (Cypris corpus, indicative; 2025–26 partial). Geographically, the United States leads with 16,671 families across 522 assignees, followed by China (7,698 families, 119 assignees), Switzerland (3,099), Germany (1,677), and Japan (1,284) (Cypris corpus, indicative; 2025–26 partial). This concentration is consistent with the bimodal picture described above: a handful of incumbents hold deep platform estates, while a much larger and more dispersed set of filers, concentrated in the US and China, works around them.

How AI-powered landscape and FTO analysis helps

A modular, multi-owner, platform-driven landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant format, antigen-arm, effector-arm, and Fc claims regardless of terminology, attribution that resolves the many owners and license chains to canonical entities, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings and deals. Because antibody-engineering advances appear in scientific literature before they are patented, reading both patents and literature gives earlier warning of where the field is heading.

Where Cypris fits

Cypris runs patent landscape and freedom-to-operate analysis for modular, platform-driven fields such as bispecific antibodies across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by layer, format scaffold, antigen arms, effector arm, Fc engineering, and manufacturing, and normalizes owners and their license chains to canonical entities, so a team sees how rights are distributed across the many parties rather than a flat list. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where new formats and target pairs emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

Why is freedom-to-operate hard for bispecific antibodies? Freedom-to-operate is hard for bispecific antibodies because a bispecific is built from a format scaffold, two antigen-binding arms, an effector arm, and Fc and manufacturing technologies, each independently patentable and often held by different owners⁵. The heterodimerization scaffolds are especially crowded. FTO must therefore be assessed layer by layer across multiple estates.

What is the chain-pairing problem? The chain-pairing problem is the challenge of ensuring that the two different heavy and light chains of a bispecific assemble into the intended molecule rather than into mismatched byproducts. Developers solve it with technologies such as knobs-into-holes, common light chains, electrostatic steering, and controlled Fab-arm exchange^6,8. Each solution is a distinct, patentable format.

What claim types create FTO risk in bispecifics? Five claim types create FTO risk: format and heterodimerization-scaffold claims, antigen-binding-arm claims, effector-arm claims, half-life and Fc-engineering claims, and manufacturing and purification claims. Each covers a distinct layer and can be held by a different owner. The format scaffold is frequently the binding constraint.

Why is format IP the binding constraint? Format IP is often the binding constraint because much of the foundational value sits in the heterodimerization scaffolds that make a bispecific manufacturable, not in any single antigen. A company can hold strong target-biology IP and still be blocked on the format it uses. That is why format licensing is central to the field.

How many bispecific antibodies are approved, and who holds the most patents? Fourteen bispecific antibodies had FDA approval through the end of 2024, nine of them T-cell engagers¹, and 2025 approvals pushed the cumulative count past fifteen². In Cypris's corpus of roughly 55,049 bispecific and T-cell-engager patent families, Regeneron, Roche, Genentech, Genmab, Amgen, and Chugai lead the assignee ranking, with the United States and China as the two largest filing jurisdictions (Cypris corpus, indicative; 2025–26 partial).

Where is the white space in bispecific antibodies? The white space includes novel formats that design around crowded heterodimerization scaffolds, new and validated target pairs, conditional or masked bispecifics, tri- and multispecific molecules, natural-killer-cell engagers, and expansion beyond oncology. The core scaffolds are crowded and licensed. The durable, defensible value is in new formats and target pairs.

Why does bispecific analysis need scientific literature? Bispecific analysis needs scientific literature because new formats, target pairs, and engineering advances appear in research before they are patented, so the literature gives the earliest signal. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

What software helps analyze the bispecific antibody patent landscape? Software for the bispecific landscape should resolve owners and license chains to canonical entities, cluster the format, antigen-arm, effector-arm, and Fc layers, search patents and scientific literature semantically, and monitor deals and new filings continuously. Cypris does this across more than 500 million patents and scientific papers using a proprietary R&D ontology, semantic search, Cypris Q, and Agentic Monitoring.

Which teams need bispecific patent landscape and FTO analysis? Bispecific patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at antibody and pharmaceutical companies, as well as investors assessing biologics assets. The modular, platform-driven landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.

‍

Endnotes

1. Strohl WR. Structure and function of therapeutic antibodies approved by the US FDA in 2024. Antibody Therapeutics. 2025. DOI: 10.1093/abt/tbaf014.
2. Crescioli S, et al. Antibodies to watch in 2026. mAbs. 2026. DOI: 10.1080/19420862.2026.2614669.
3. U.S. Food and Drug Administration. Oncology (Cancer) / Hematologic Malignancies approval notification — zanidatamab (Ziihera), accelerated approval, November 20, 2024. fda.gov.
4. van de Donk NWCJ, Zweegman S. T-cell-engaging bispecific antibodies in cancer. The Lancet. 2023. DOI: 10.1016/s0140-6736(23)00521-4.
5. Brinkmann U, Kontermann RE. Bispecific antibodies. Drug Discovery Today. 2015. DOI: 10.1016/j.drudis.2015.02.008.
6. Brinkmann U, Kontermann RE. The making of bispecific antibodies. mAbs. 2017. DOI: 10.1080/19420862.2016.1268307.
7. Falkowski VM, et al. Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies. Frontiers in Immunology. 2024. DOI: 10.3389/fimmu.2024.1376096.
8. Rodriguez M, et al. Bispecific antibody process development: assembly and purification of knob and hole bispecific antibodies. Biotechnology Progress. 2017. DOI: 10.1002/btpr.2590.
9. Cypris platform corpus analysis, bispecific antibody / T-cell-engager patent families. Indicative figures; 2025–2026 partial

Sodium-ion batteries have moved from laboratory alternative to commercial reality, and their patent landscape is distinctive because the field is consolidating around a few competing chemistries just as production scales. A sodium-ion cell works on the same intercalation principle as a lithium-ion cell but shuttles sodium ions instead of lithium, which trades lower energy density for real advantages: sodium is abundant and cheap, the cells are safer and perform better in the cold, and they avoid the constrained lithium and cobalt supply chains, making them attractive for grid storage and entry-level electric vehicles. The intellectual property divides across several regions, each a distinct area of patenting: the cathode, where three chemistries compete, layered transition-metal oxides, Prussian blue analogs, and polyanionic phosphates, each with different trade-offs in energy density, cost, and cycle life;⁵ the anode, dominated by hard carbon, whose disordered microstructure stores sodium through a combination of sloping and plateau capacity and whose reversible and irreversible capacity are set by that microstructure;¹,² the electrolyte; and the cell and manufacturing design, much of which can be adapted from existing lithium-ion production lines. Because a competitive cell depends on several of these layers, freedom-to-operate and white space analysis must span the cathode chemistries and the other layers together.

The landscape is concentrated and moving quickly. Commercial sodium-ion products have launched: CATL introduced a first-generation cell in 2021 and, in 2025, its higher-density Naxtra series, which the company reports reaches an energy density of about 175 watt-hours per kilogram, operates from roughly −40 to 70 degrees Celsius, and exceeds ten thousand cycles, positioning it close to lithium iron phosphate cells for entry-level vehicles.⁶ In early 2026, CATL and Changan announced what CATL describes as the first mass-production passenger vehicle powered by sodium-ion cells.⁷ Activity is heavily concentrated among a small number of large battery manufacturers pursuing full-stack portfolios that span cathode, anode, electrolyte, and manufacturing, with a broad tail of materials specialists and research institutes. This shows clearly in the patent record: across the Cypris corpus of more than 500 million patents and scientific papers, the sodium-ion set is the largest of any topic Cypris tracks in this area, on the order of 37,408 families, and grew from about 1,585 in 2020 to roughly 5,970 in 2024, with the most active assignees led by CATL and its recycling affiliate Brunp alongside research institutes such as the Institute of Physics of the Chinese Academy of Sciences and the Dalian Institute of Chemical Physics, and China overwhelmingly dominant on geography (about 24,235 families) ahead of the United States (about 1,931) and Japan (about 1,669); 2025 and 2026 counts are partial because of the publication lag.

The strategic question is which chemistry and layer to back, and the white space sits where performance and cost are hardest to reconcile. On the cathode side, raising energy density and cycle life while holding down cost is the central problem, and each of the three chemistries has open ground.⁵ On the anode side, hard carbon is the workhorse, but improving its initial coulombic efficiency, its capacity, and the cost and consistency of its precursors is a large, active opportunity, with precursor selection, such as phenolic-resin-derived carbons, itself a patentable lever, as are novel and anode-light or anode-free designs.¹,²,³,⁴ Electrolytes tuned for sodium and recycling processes adapted to sodium chemistry are further layers. Reading the landscape by chemistry, layer, and owner, and tracking both the patents and the underlying materials research, is what separates a crowded region from an open one.

Where the sodium-ion white space is

High-performance cathodes. Raising energy density and cycle life while holding down cost, across layered oxides, Prussian blue analogs, and polyanionic phosphates, is the central problem and each chemistry has open ground.⁵

Hard-carbon anode improvement. Improving initial coulombic efficiency, capacity, and low-cost, consistent precursors for hard carbon is a large, active layer.¹,²,³

Anode-light and anode-free designs. Cell designs that reduce or omit the anode active layer for higher energy density are an emerging, differentiating area.

Sodium-tuned electrolytes. Electrolytes and interphase chemistries optimized for sodium's larger ion are a distinct layer affecting performance and durability.

Sodium recycling. Recovery and recycling processes adapted to sodium-ion chemistry are an early layer that will matter as volumes grow.

How AI-powered landscape and white space analysis helps

Resolving a landscape that spans three cathode chemistries and several cell layers, concentrated among a few large filers, requires more than keyword search. AI-powered analysis addresses this with semantic search that clusters activity by chemistry and layer across varied terminology, attribution that normalizes filers to canonical entities and tracks new entrants, and continuous monitoring that keeps pace with a fast-scaling field. Because sodium-ion advances appear in scientific and materials literature before they are patented, reading both patents and literature gives the earliest signal of where durable, low-cost cells are emerging.

Where Cypris fits

Cypris runs patent landscape and white space analysis for fast-scaling energy fields such as sodium-ion batteries across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters activity by cathode chemistry, layered oxide, Prussian blue analog, and polyanionic phosphate, and by layer, anode, electrolyte, cell, and manufacturing, and normalizes filers to canonical entities, so a team can resolve which chemistries and layers are crowded and which remain open as white space, and can track new entrants as the field scales. Semantic search across patents and scientific literature connects filings to the underlying materials research, which is where sodium-ion advances appear first. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the clustering, attribution, and gap analysis, and Agentic Monitoring tracks a defined chemistry over time and flags new patents and papers as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

What is the sodium-ion battery patent landscape? The sodium-ion battery patent landscape is the set of patents covering cells that store energy by shuttling sodium ions rather than lithium. It divides across three cathode chemistries, layered oxides, Prussian blue analogs, and polyanionic phosphates, plus the hard-carbon anode, electrolytes, and cell and manufacturing design. Each is a distinct region of patenting.

Why are sodium-ion batteries gaining ground? Sodium-ion batteries are gaining ground because sodium is abundant and cheap, the cells are safer and perform better in cold weather, and they avoid constrained lithium and cobalt supply chains. They trade lower energy density for these advantages, which suits grid storage and entry-level electric vehicles. Commercial launches have moved the technology from research to market.

What are the main sodium-ion cathode chemistries? The main cathode chemistries are layered transition-metal oxides, which offer higher energy density; Prussian blue analogs, which offer low cost; and polyanionic phosphates, which offer stability and long cycle life. Each carries different trade-offs and its own IP. The choice of chemistry shapes both the technical and the freedom-to-operate picture.

Where is the white space in sodium-ion batteries? The white space includes higher-performance cathodes across all three chemistries, hard-carbon anode improvement and low-cost precursors, anode-light and anode-free designs, sodium-tuned electrolytes, and sodium recycling. Activity is concentrated among a few large filers, leaving room in the materials and design layers. The central problem is reconciling energy density, cycle life, and cost.

Why is the hard-carbon anode a focus? The hard-carbon anode is a focus because it is the workhorse anode for sodium-ion cells, and its initial coulombic efficiency, capacity, and precursor cost and consistency are key determinants of cell performance and economics. Its disordered microstructure governs how much sodium it stores reversibly. Improving these, including through precursor selection, is an active, large layer of the landscape.

Why does sodium-ion analysis need scientific literature? Sodium-ion analysis needs scientific literature because cathode, anode, and electrolyte advances appear in materials research before they are patented, so the literature gives the earliest signal. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

What software helps analyze the sodium-ion battery patent landscape? Software for the sodium-ion landscape should cluster activity by cathode chemistry and cell layer, resolve filers to canonical owners, search patents and scientific literature semantically, and monitor a fast-scaling field continuously. Cypris does this across more than 500 million patents and scientific papers using a proprietary R&D ontology, semantic search, Cypris Q, and Agentic Monitoring.

Which teams use sodium-ion patent landscape analysis? Sodium-ion patent landscape analysis is used by R&D, innovation, IP, and strategy teams at battery and materials makers, automotive and energy-storage companies, and their suppliers, as well as investors assessing the sector. It informs which chemistry and layer to back, where to file, and where competitors are concentrated. Cypris serves hundreds of enterprise customers across energy, advanced materials, chemicals, and other regulated industries.

Endnotes

1. Xu, Z., Guo, X., Xie, F., & Titirici, M.-M. (2020). Hard carbons for sodium-ion batteries and beyond. Progress in Energy, 2(4). https://doi.org/10.1088/2516-1083/aba5f5
2. Irisarri, E., Ponrouch, A., & Palacín, M. R. (2015). Review — hard carbon negative electrode materials for sodium-ion batteries. Journal of the Electrochemical Society, 162(14). https://doi.org/10.1149/2.0091514jes
3. Sagues, W. J., Park, S., et al. (2024). Phenolic-resin-derived hard carbon anode for sodium-ion batteries: a review. ACS Energy Letters, 9(6). https://doi.org/10.1021/acsenergylett.4c00688
4. Sun, N., Peng, H., Liu, Z., et al. (2024). Recent progress in hard carbon anodes for sodium-ion batteries. Advanced Engineering Materials, 26(9). https://doi.org/10.1002/adem.202302063
5. Zhu, X., He, Y., Liu, Y., & Wu, Y. (2024). Review of cathode materials for sodium-ion batteries. Progress in Solid State Chemistry, 74. https://doi.org/10.1016/j.progsolidstchem.2024.100452
6. Contemporary Amperex Technology Co., Ltd. (2025). Naxtra battery breakthrough and dual-power architecture: CATL pioneers the multi-power era. https://www.catl.com/en/news/6401.html
7. Contemporary Amperex Technology Co., Ltd. (2026). CATL and Changan launch the world's first mass-production sodium-ion passenger vehicle. https://www.catl.com/en/news/6720.html

‍

Humanoid robotics has moved from research demonstrations toward commercialization, and its patent landscape is being staked out quickly and unevenly. A humanoid robot integrates several distinct technology layers, each independently patentable: the actuators and joints that produce motion, the perception and sensing systems that let the robot model its surroundings, the motion, balance, and whole-body control that keep it upright and coordinated, and the embodied-AI layer that connects high-level decision-making to physical action. Companies such as Tesla, Figure, and Unitree have pushed the field into a commercialization race, and peer-reviewed patent analyses of humanoid robotics describe a cross-disciplinary field whose filings span mechatronics, control, and perception and identify the subfields where activity concentrates.¹,²

The geographic story dominates the data. An analysis across the Cypris corpus of more than 500 million patents and scientific papers finds a humanoid- and bipedal-robotics family set in which China holds roughly two-thirds of all-time families, about 8,804, versus about 711 for the United States and about 407 for Japan. The concentration is sharper in recent years: over the 2020 to 2025 window, Chinese applicants account for roughly three-quarters of families, about 3,169, far ahead of the United States, about 142, and Japan, about 83, with 2025 counts partial because of the roughly eighteen-month publication lag. Research output tells a different story from filing volume: scientometric analysis of the humanoid-robotics literature finds the United States, Japan, and Germany leading publication output, a reminder that leadership in papers and leadership in patent volume do not always coincide, and that raw family counts measure filing activity rather than influence or quality.³

The timing is as striking as the geography. Across the Cypris corpus, humanoid- and bipedal-robotics filings in the 2020 to 2025 window were roughly flat through 2022, around 300 to 320 per year, before accelerating sharply, to about 387 in 2023, 857 in 2024, and 1,915 in 2025 on a partial count, indicating a shift from enabling technologies toward the physical embodiment and control of the robots themselves. The most active assignees in the set span regions and sectors: SoftBank's Aldebaran, China's UBTech, Honda, Boston Dynamics, Toyota, and Sony, alongside a broad tail of Chinese universities such as Zhejiang University, Harbin Institute of Technology (Shenzhen), and Tsinghua University, so incumbents anchor the established positions while a large university base drives Chinese breadth.

Policy priorities and the technical frontier shape where the landscape is heading. National industrial strategies have elevated robotics and embodied AI, and patent-graph analyses that link policy signals to filings map where those priorities are translating into intellectual property.⁹ The defining unsolved technical challenge, and therefore the most contested and most valuable IP frontier, is the integration of AI with motion control: end-to-end learning, embodied-AI and whole-body control models, and sim-to-real transfer that bridge high-level decision-making and low-level motion execution.⁴,⁵,⁶ Actuator design is a second critical layer, where torque density, backdrivability, and thermal performance for bipedal locomotion at production cost are the central problems, and where both electric and hydraulic actuation approaches remain under active development.⁷,⁸ Across the Cypris corpus, the actuator and joint layer is by far the most heavily patented, on the order of 8,000 families, followed by perception and sensing, around 4,100, motion and balance control, around 2,200, and the still-small but fastest-emerging embodied-AI and learning-based control layer, around 1,400. Because applications publish about eighteen months after filing, the 2024 to 2025 surge is under-represented, so the current frontier is more active than granted-patent counts suggest.

Where the humanoid-robotics white space is

Embodied-AI motion integration. Connecting learned high-level behavior to low-level motion control is the defining unsolved problem and the fastest-emerging, still comparatively small IP layer, leaving room for high-value positions.⁴

Actuator design. Torque density, backdrivability, and thermal performance for bipedal locomotion at production cost are central engineering problems and a heavily worked but still-advancing layer.⁷

Dexterous manipulation. Robust hands and fine manipulation remain difficult, and IP here is less crowded than locomotion.

Long-duration autonomy. Power, thermal management, and reliability for extended operation are enabling problems that gate deployment.

Cost-reduction engineering. Designs and processes that lower the cost of production-scale humanoids are a distinct and commercially decisive area.

How AI-powered landscape and white space analysis helps

Resolving a multi-layer, geographically lopsided, fast-accelerating landscape requires more than keyword search. AI-powered analysis addresses this with semantic search that clusters activity by layer, actuators, perception, control, and embodied AI, across varied terminology, attribution that normalizes corporate and university filers to canonical entities and captures the regional structure, and continuous monitoring that keeps pace with a surging field. Because humanoid-robotics advances appear in scientific literature before they are patented, and because research and patent leadership diverge here, reading both patents and literature gives the fullest and earliest signal of where the frontier is moving.

Where Cypris fits

Cypris runs patent landscape and white space analysis for fast-accelerating, multi-layer fields such as humanoid robotics across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters activity by layer, actuators and joints, perception and sensing, motion and balance control, and embodied AI, and normalizes corporate and university filers to canonical entities, so a team can resolve which layers are crowded and which remain open as white space, and can see the regional structure clearly rather than as a flat list. Semantic search across patents and scientific literature connects filings to the underlying robotics and machine-learning research, which is where embodied-AI advances appear first, and where patent and research leadership diverge. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the clustering, attribution, and gap analysis, and Agentic Monitoring tracks a defined layer over time and flags new patents and papers as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

How fast is humanoid-robotics patenting growing? Humanoid-robotics patenting is surging as companies race toward commercialization. An analysis of the Cypris corpus finds filings roughly flat through 2022 before accelerating sharply from 2023, rising from a few hundred per year to well over a thousand by 2025 on a partial count. The acceleration reflects a shift from enabling technologies toward the physical embodiment and control of the robots themselves.

Who leads in humanoid-robotics patents? China leads in humanoid-robotics patent volume, holding roughly two-thirds of all-time families and about three-quarters of families filed since 2020 in the Cypris corpus, well ahead of the United States and Japan. Research output tells a different story: scientometric analysis finds the United States, Japan, and Germany leading humanoid-robotics publications. Leadership in patents and in papers does not always coincide.

Why do patent counts and research output differ in humanoid robotics? Patent counts and research output differ because family counts measure filing volume, not scientific influence or patent quality, and the two can diverge. China leads on humanoid-robotics patent volume, while the United States, Japan, and Germany lead on publications. A full assessment therefore weighs filing volume against the underlying research rather than treating raw counts as a measure of value.

What are the main technology layers in humanoid robotics? The main layers are actuators and joints, perception and sensing, motion and balance control, and embodied AI that links decision-making to action. Each is independently patentable and often held by different owners. In the Cypris corpus the actuator layer is by far the most heavily patented, and embodied AI is the smallest but fastest-emerging.

What is the defining technical challenge in humanoid robotics? The defining technical challenge is integrating AI with motion control, connecting high-level, learned decision-making to low-level physical action through embodied-AI and whole-body control models and sim-to-real transfer. It is the most contested and most valuable IP frontier. It is also where the patent landscape is expanding fastest.

Where is the white space in humanoid robotics? The white space includes embodied-AI motion integration, actuator design for torque density and efficiency, dexterous manipulation, long-duration autonomy, and cost-reduction engineering for production-scale robots. Embodied-AI motion integration is the fastest-emerging and still comparatively small layer. Manipulation and autonomy are less crowded than locomotion.

Why does humanoid-robotics analysis need scientific literature? Humanoid-robotics analysis needs scientific literature because embodied-AI, control, and actuation advances appear in research before they are patented, and because patent and research leadership diverge in this field, so the literature gives the earliest and fullest signal. Analyzing patents alone gives a lagging and partial view. Cypris analyzes both across more than 500 million patents and scientific papers.

Which teams use humanoid-robotics patent landscape analysis? Humanoid-robotics patent landscape analysis is used by R&D, IP, and strategy teams at robotics companies, automotive and electronics firms, component and actuator suppliers, and universities, as well as investors assessing robotics assets. It informs which layer to back, where to file, and where competitors are concentrated. Cypris serves hundreds of enterprise customers across research-intensive and regulated industries.

Endnotes

1. Kumari, R., Lee, B.-H., Jeong, J. Y., Choi, K.-S., & Choi, K.-N. (2019). Topic modelling and social network analysis of publications and patents in humanoid robot technology. Journal of Information Science. https://doi.org/10.1177/0165551519887878
2. Jang, D.-S., Park, S., Kim, G., Lee, J., & Kim, J. (2016). A hybrid method of analyzing patents for sustainable technology management in humanoid robot industry. Sustainability, 8(5), 474. https://doi.org/10.3390/su8050474
3. Kumar, V., & Singh, K. (2026). Global research trends and thematic evolution in humanoid robotics: a scientometric and text mining study. Discover Artificial Intelligence. https://doi.org/10.1007/s44163-026-01251-x
4. Wang, H. C., Chen, J., Zeng, W., Jin, X., & Yu, T. (2025). A survey of behavior foundation model: next-generation whole-body control system of humanoid robots. IEEE Transactions on Pattern Analysis and Machine Intelligence. https://doi.org/10.1109/tpami.2025.3649177
5. Yuan, Y., & Zhao, W. (2025). Development of intelligent robots in the wave of embodied intelligence. National Science Review. https://doi.org/10.1093/nsr/nwaf159
6. Humphreys, J., Zhou, C., Peng, T., & Bao, L. (2025). Deep reinforcement learning for robotic bipedal locomotion: a brief survey. Artificial Intelligence Review. https://doi.org/10.1007/s10462-025-11451-z
7. Niiyama, R. (2022). Soft actuation and compliant mechanisms in humanoid robots. Current Robotics Reports. https://doi.org/10.1007/s43154-022-00084-7
8. Faudzi, A. A. M., & Suzumori, K. (2018). Trends in hydraulic actuators and components in legged and tough robots: a review. Advanced Robotics. https://doi.org/10.1080/01691864.2018.1455606
9. Zheng, Y. (2026). Discovering technology opportunities in humanoid robotics and embodied intelligence: a policy-semantic heterogeneous patent graph approach. Mendeley Data. https://doi.org/10.17632/hk63kt4swb

‍